Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

NINLARO Drug Profile

« Back to Dashboard

Which patents cover Ninlaro, and what substitute generic drugs are available?

Ninlaro is a drug marketed by Millennium Pharms and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and fifty-five patent family members in forty-one countries.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this compound. Additional details are available on the ixazomib citrate profile page.

Summary for Tradename: NINLARO

Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list6
Clinical Trials: see list15
Patent Applications: see list3
Drug Prices:see details
DailyMed Link:NINLARO at DailyMed

Pharmacology for Tradename: NINLARO

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes9,233,115► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes8,546,608► SubscribeY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo8,530,694► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NINLARO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,018,301► Subscribe
8,772,536Proteasome inhibitors► Subscribe
7,576,206Proteasome inhibitors and methods of using the same► Subscribe
7,915,236Proteasome inhibitors and methods of using the same► Subscribe
8,058,262Proteasome inhibitors and methods of using the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NINLARO

Country Document Number Estimated Expiration
Serbia52435► Subscribe
Costa Rica20160015► Subscribe
Japan2014144981► Subscribe
Taiwan200529810► Subscribe
Japan5926319► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc